跳至主要内容
临床试验/NCT05024344
NCT05024344招募中不适用

Erector Spinae Plane Block Versus Control for Pain Control Following Percutaneous Nephrolithotomy: A Randomized, Double-Blind, Placebo Controlled Study

University of Tennessee Medical Center2 个研究点 分布在 1 个国家目标入组 128 人开始时间: 2021年8月9日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
招募中
入组人数
128
试验地点
2
主要终点
Opioid consumption (MME)

研究概览

简要总结

The purpose of this study is to investigate the use of the erector spinae (ESP) block in reducing the morphine milligram equivalent (MME) consumption post percutaneous nephrolithotomy. Objectives:

  1. - Determine if there is a significant effect on post percutaneous nephrolithotomy MME consumption with the usage of an ESP block vs. saline control.
  2. - Determine if there is a significant effect on reported pain levels with the use of an ESP block vs. saline control in post percutaneous nephrolithotomies.

详细描述

This is a double-blind, randomized control trial involving 128 subjects undergoing an elective percutaneous nephrolithotomy. All subjects who meet all inclusion and exclusion criteria will be equally randomized on the day of the procedure by operating room pharmacy into either the ESP block or the control block. An interim analysis at the sample size required for a large effect size (n = 52, with n = 26 in each treatment arm) will be performed. In order to blind the anesthesiologist performing the block, the control arm will be equally randomized by the pharmacist at the time of distributing the pre-filled syringes for the ESP block procedure. Randomization will occur with the use of a random number generator with 1:1 ESP:Control allocation ratio.

Subjects will be followed at Pre-op and the 24-h, 48-h, 7 days and 30 days post operatively to assess the quality of recovery utilizing the Quality of Recovery-15 (QoR-15) questionnaire, VAS pain scale, and opioid consumption. Intraoperative MMEs, PACU MMEs, total MME's, FLACC scores at 30 minutes/1 hour VAS scores at 1 hour/2 hours/6 hours/24 hours, PACU LOS, hospital LOS, time to first flatus will be documented in patient chart, reviewed by study personnel and uploaded into a password protected database on the UTMCK server.

All aspects of the study and consent forms will be IRB approved prior to implementation. Potential candidates will be selected for consent based on chart review and surgery scheduling.

  • The Surgeon will initially approach potential subjects and provide them with a copy of the consent form to take home and read prior to pre-anesthesia testing.
  • At the subject's pre-anesthesia testing appointment, the research staff will explain the risks and benefits of the study, answer any questions, and obtain consent to participate.
  • The Biostatistician will randomize the subjects with a random number generator. Once randomized, a blinded package labeled "ESP" or "Control" will be delivered to the regional anesthesia team containing the following:

ESP

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults, male and female greater than or equal to 18 years of age and undergoing non-emergent percutaneous nephrolithotomy Monday through Friday between the hours of 6:00AM and 4:00PM.
  • Female participants of childbearing potential will be required to provide a negative pregnancy test.
  • Ability to understand and teach back consent for the procedure.
  • Willingness to sign consent for procedure.
  • English speaking.

排除标准

  • Emergent surgery status.
  • Local infection
  • Allergy to local anesthetics.
  • Recreational drug use.
  • Inability to provide informed consent.
  • Pregnancy or breastfeeding.
  • History of Guillain-Barre' Syndrome.
  • Underlying medical conditions that would post a significant risk to the patient.
  • Opioid use >90 days in the year leading up to surgery.

研究组 & 干预措施

ESP Group

Active Comparator

One 30mL syringe containing 30mL of 0.5% ropivacaine and 4 mg of dexamethosone-

干预措施: Ropivacaine 0.5% Injectable Solution (Drug)

ESP Group

Active Comparator

One 30mL syringe containing 30mL of 0.5% ropivacaine and 4 mg of dexamethosone-

干预措施: Dexamethasone (Drug)

ESP Group

Active Comparator

One 30mL syringe containing 30mL of 0.5% ropivacaine and 4 mg of dexamethosone-

干预措施: Erector Spinae Plane Block (Procedure)

Sham Group

Sham Comparator

One 30mL syringe containing 30mL of preservative free normal saline

干预措施: Erector Spinae Plane Block (Procedure)

结局指标

主要结局

Opioid consumption (MME)

时间窗: First 24 hours postoperative

Opioid consumption (MME) in the first 24 hours postoperative

次要结局

  • Hospital LOS(Number of days in hospital (inpatient) from day of surgery (day 1) until discharge post-surgery in 24 hour increments up to 30 days)
  • VAS score(First 24 hours after surgery.)
  • Opioid use during first 24 hours after surgery(24 hours)
  • QoR-15(24 hours, 48 hours, 7 days, and 30 days after surgery)
  • Opioid use during 30 days post hospital discharge(30 days)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

ESP Block vs Control for Pain Control Following... | 临床试验